Table 1.
Main clinicopathological features of patients enrolled in the CHRONOS trial
| Characteristic | Study population |
|---|---|
| (n = 27) | |
| Age (median; range of years) | 64 (42–80) |
| Gender (n, %) | |
| Male | 16 (59) |
| Female | 11 (41) |
| ECOG status (n, %) | |
| 0–1 | 26 (96) |
| 2 | 1 (4) |
| Primary tumor sidedness | |
| Right colon * | 5 (18) |
| Left colon § | 17 (63) |
| Rectum | 5 (18) |
| Stage at initial diagnosis (n, %) | |
| Stage I–III | 12 (44) |
| Stage IV | 15 (56) |
| Mismatch repair status (n, %) | |
| MSI | 0 (0) |
| MSS | 27 (100) |
| Number of previous lines of therapy (median, range) | 3 (2–6) |
| Oxaliplatin-containing regimens (n, %) | 27 (100) |
| Irinotecan-containing regimens (n, %) | 25 (93) |
| Anti-VEGF (n, %) | 16 (59) |
| Regorafenib (n, %) | 7 (26) |
| Trifluridine–tipiracil (n; %) | 6 (22) |
| Previous anti-EGFR treatment | |
| Combination with chemotherapy (n, %) | 27 (100) |
| - Previous rechallenge (n, %) | 2 (7) |
| - Previous reintroduction (n, %) | 7 (26) |
| Anti-EGFR monotherapy (n, %) | 0 (0) |
| Type of previous anti-EGFR monoclonal antibody | |
| Panitumumab | 15 (55) |
| Cetuximab | 11(41) |
| Both | 1 (4) |
* Located in caecum, ascending colon, liver flexure and transverse colon. § Located in splenic flexure, descending colon and sigmoid colon. VEGF, vascular endothelial growth factor; ECOG, Eastern Cooperative Oncology Group; MSS, microsatellite stable; MSI, microsatellite instable, EGFR, epidermal growth factor receptor.